Select therapeutic use:
Indications for SERNIVO:
Mild-to-moderate plaque psoriasis.
≥18yrs: apply to affected areas twice daily for up to max 4 weeks; discontinue when control is achieved. Do not occlude.
<18yrs: not recommended.
Not for oral, ophthalmic, or intravaginal use. Systemic absorption increased by altered skin barrier, inflamed skin, prolonged use, application to large surface area, or use of occlusive dressings. Discontinue or reduce dose or potency if HPA axis suppression, Cushing's syndrome, hyperglycemia, glucosuria, or irritation occurs. Do not use on face, axillae, or groin, or if atrophy is present at treatment site. Allergic contact dermatitis. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.
Pruritus, burning, stinging, pain, atrophy, telangiectasia, dermatitis, discoloration, folliculitis, skin rash; HPA axis suppression (esp. in children).